{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:00:19Z","timestamp":1791259219863,"version":"4.1.0"},"reference-count":140,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1378\/chest.126.3_suppl.265s","type":"journal-article","created":{"date-parts":[[2004,9,21]],"date-time":"2004-09-21T18:47:46Z","timestamp":1095792466000},"page":"265S-286S","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"special_numbering":"S","title":["New Anticoagulant Drugs"],"prefix":"10.1016","volume":"126","author":[{"given":"Jeffrey I.","family":"Weitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meyer M.","family":"Samama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.126.3_suppl.265S_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199201233260406","article-title":"The pathogenesis of coronary artery disease and the acute coronary syndromes","volume":"326","author":"Fuster","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib2","series-title":"Hemostasis and thrombosis: basic principles and clinical practice","first-page":"1123","article-title":"The structure of thrombi","author":"Freiman","year":"1987"},{"key":"10.1378\/chest.126.3_suppl.265S_bib3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(69)90002-6","article-title":"Natural history of postoperative deep-vein thrombosis","volume":"2","author":"Kakkar","year":"1969","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.265S_bib4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1259\/0007-1285-44-525-653","article-title":"The origin of deep vein thrombosis: a venographic study","volume":"44","author":"Nicolaides","year":"1971","journal-title":"Br J Radiol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib5","doi-asserted-by":"crossref","first-page":"132S","DOI":"10.1378\/chest.119.1_suppl.132S","article-title":"Prevention of venous thromboembolism","volume":"119","author":"Geerts","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.126.3_suppl.265S_bib6","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1172\/JCI112687","article-title":"Binding of fibrinogen to human monocytes","volume":"78","author":"Altieri","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.265S_bib7","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.85.20.7462","article-title":"Adhesive receptor Mac-1 coordinates the activation of factor on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade","volume":"85","author":"Altieri","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.265S_bib8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1055\/s-0037-1616128","article-title":"Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation","volume":"86","author":"McEver","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0037-1613012","article-title":"P-selectin and PSGL-1: exploiting connections between inflammation and venous thrombosis","volume":"87","author":"McEver","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib10","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1073\/pnas.96.5.2311","article-title":"Blood-borne tissue factor: another view of thrombosis","volume":"96","author":"Giesen","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.265S_bib11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJM199203193261205","article-title":"Molecular and cellular biology of blood coagulation","volume":"326","author":"Furie","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib12","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1055\/s-0038-1656125","article-title":"Tissue factor expression during monocyte-macrophage differentiation","volume":"77","author":"van den Eijnden","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib13","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1161\/01.ATV.17.12.3399","article-title":"Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity","volume":"17","author":"Neumann","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.ATV.0000046238.23903.FC","article-title":"The dynamics of thrombin formation","volume":"23","author":"Mann","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-2007-993291","article-title":"Factor XI activation by thrombin and factor XIa","volume":"19","author":"Gailani","year":"1993","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1055\/s-0038-1642658","article-title":"Tissue factor pathway inhibitor","volume":"74","author":"Broze","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-0037-1616203","article-title":"Roles of platelets and factor XI in the initiation of blood coagulation by thrombin","volume":"86","author":"Walsh","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib18","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199105303242206","article-title":"Heparin","volume":"324","author":"Hirsh","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib19","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1083\/jcb.111.3.1293","article-title":"Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta","volume":"111","author":"de Agostini","year":"1990","journal-title":"J Cell Biol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-0038-1657503","article-title":"The protein C pathway: new insights","volume":"78","author":"Esmon","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0037-1615840","article-title":"Endothelial protein C receptor","volume":"82","author":"Esmon","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-0037-1615841","article-title":"The plasminogen (fibrinolytic) system","volume":"82","author":"Collen","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib23","doi-asserted-by":"crossref","first-page":"d341","DOI":"10.2741\/kim","article-title":"Annexin II: a plasminogen-plasminogen activator co-receptor","volume":"7","author":"Kim","year":"2002","journal-title":"Front Biosci"},{"key":"10.1378\/chest.126.3_suppl.265S_bib24","first-page":"292","article-title":"The FVII activating protease cleaves single-chain plasminogen activators","volume":"76","author":"Roemich","year":"1999","journal-title":"Haemostasis"},{"key":"10.1378\/chest.126.3_suppl.265S_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00001721-200207000-00008","article-title":"The frequent Marburg I polymorphism impairs the prourokinase activating potency of the factor VII-activating protease (FSAP)","volume":"13","author":"Roemisch","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.126.3_suppl.265S_bib26","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1161\/01.CIR.0000055189.18831.B1","article-title":"Marburg I polymorphism of factor VII-activating protease: a prominent risk predictor of carotid stenosis","volume":"107","author":"Willeit","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib27","doi-asserted-by":"crossref","first-page":"16603","DOI":"10.1074\/jbc.271.28.16603","article-title":"TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex","volume":"271","author":"Bajzar","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.265S_bib28","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1097\/00003246-200111000-00007","article-title":"Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study","volume":"29","author":"Abraham","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.20021088","article-title":"New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins","volume":"196","author":"Esmon","year":"2002","journal-title":"J Exp Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"Abraham","year":"2003","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.265S_bib32","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1073\/pnas.92.13.6152","article-title":"Ancylostoma caninumanticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa","volume":"92","author":"Cappello","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.265S_bib33","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1073\/pnas.93.5.2149","article-title":"Anticoagulant repertoire of the hookwormAncylostoma caninum","volume":"93","author":"Stanssens","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.265S_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/hc2601.091386","article-title":"Dose-response study of recombinant factor VIIa\/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement","volume":"104","author":"Lee","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib35","first-page":"83","article-title":"Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100Escherichia coliin the baboon","volume":"26","author":"Taylor","year":"1996","journal-title":"Haemostasis"},{"key":"10.1378\/chest.126.3_suppl.265S_bib36","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1161\/01.CIR.92.10.3041","article-title":"Influence of blockade at specific levels of the coagulant cascade on restenosis in a rabbit atherosclerotic femoral artery injury model","volume":"92","author":"Jang","year":"1995","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib37","first-page":"312","volume":"36","author":"Lincoff","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib38","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.V97.8.2308","article-title":"Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex","volume":"97","author":"Rezaie","year":"2001","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.265S_bib39","doi-asserted-by":"crossref","first-page":"17663","DOI":"10.1074\/jbc.M011586200","article-title":"The use of prothrombin (S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation","volume":"276","author":"Brufatto","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.265S_bib40","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1055\/s-0038-1649967","article-title":"Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107\/ORG31540) with high affinity to antithrombin III in man","volume":"74","author":"Boneu","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib41","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib42","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib43","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.265S_bib44","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.265S_bib45","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib46","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archinte.163.11.1337","article-title":"Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study","volume":"163","author":"Eriksson","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib47","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1001\/archinte.162.17.1966","article-title":"Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study","volume":"162","author":"Prandoni","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib48","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1001\/archinte.160.14.2208","article-title":"Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin\/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison; North American Fragmin Trial Investigators","volume":"160","author":"Hull","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib49","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1055\/s-0037-1615775","article-title":"Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis","volume":"85","author":"Cohen","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(00)05249-1","article-title":"Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta analysis of the randomised trials","volume":"358","author":"Eikelboom","year":"2001","journal-title":"Lancet"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.265S_bib51","first-page":"P2046","article-title":"Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (artemis) [abstract]","volume":"1","author":"Cohen","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.265S_bib52","first-page":"OC006","article-title":"A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus Study [abstract]","volume":"1","author":"Agnelli","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib53","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib54","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"The MATISSE Investigators","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib55","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/euhj.2001.2777","article-title":"A synthetic factor-Xa inhibitor (ORG31540\/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study","volume":"22","author":"Coussement","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.126.3_suppl.265S_bib56","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1161\/hc0502.104277","article-title":"Meeting highlights: American Heart Association scientific sessions 2001","volume":"105","author":"Ferguson","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib57","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","article-title":"Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.265S_bib58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1538-7836.2003.00516.x","article-title":"A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation","volume":"2","author":"Persist Investigators","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib59","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1161\/01.CIR.0000016351.12759.52","article-title":"First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation","volume":"105","author":"Dyke","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib60","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMsa020969","article-title":"An economic evaluation of activated protein C treatment for severe sepsis","volume":"347","author":"Manns","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib61","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1055\/s-2007-994962","article-title":"Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans","volume":"25","author":"Ettingshausen","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib62","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1182\/blood.V96.12.3719","article-title":"An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia","volume":"96","author":"White","year":"2000","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.265S_bib63","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJM200108093450603","article-title":"Dysfunction of endothelial protein C activation in severe meningococcal sepsis","volume":"345","author":"Faust","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib64","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1055\/s-0037-1615902","article-title":"Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation","volume":"82","author":"Maruyama","year":"1999","journal-title":"Thromb Haemost"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.265S_bib65","first-page":"OC330","article-title":"A dose-resonse study of a recombinant human soluble thrombomodulin (ART-123) for prevention of venous thromboembolism after unilateral total hip replacement [abstract]","volume":"1","author":"Kearon","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib66","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/hc0802.104331","article-title":"Direct thrombin inhibitors in acute coronary syndromes: present and future","volume":"105","author":"Weitz","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib67","doi-asserted-by":"crossref","first-page":"V275","DOI":"10.1016\/S0049-3848(02)00093-2","article-title":"Direct thrombin inhibitors","volume":"106","author":"Weitz","year":"2002","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.265S_bib68","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-2007-999007","article-title":"Hirudins: from leeches to man","volume":"22","author":"Wallis","year":"1996","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib69","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/00019501-199606000-00004","article-title":"Biochemistry and biology of hirudin","volume":"7","author":"Toschi","year":"1996","journal-title":"Coron Artery Dis"},{"key":"10.1378\/chest.126.3_suppl.265S_bib70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0009-9236(97)90151-X","article-title":"Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin","volume":"62","author":"Lefevre","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.265S_bib71","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.CIR.96.3.769","article-title":"Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study: Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators","volume":"96","author":"Anonymous","year":"1997","journal-title":"Circulation"},{"issue":"9151","key":"10.1378\/chest.126.3_suppl.265S_bib72","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(98)07332-2","volume":"353","author":"Anonymous","year":"1999","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.265S_bib73","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/01.CIR.90.4.1624","article-title":"the TIMI 9A Investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial","volume":"90","author":"Antman","year":"1994","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib74","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1161\/01.CIR.90.4.1638","article-title":"Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK)","volume":"90","author":"Neuhaus","year":"1994","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib75","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.CIR.90.4.1631","article-title":"Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes: the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa investigators","volume":"90","author":"The GUSTO IIa Investigators","year":"1994","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib76","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction: the GUSTO Investigators","volume":"329","author":"The GUSTO Investigators","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib77","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes: the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators","volume":"335","author":"The GUSTO IIb Investigators","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib78","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0735-1097(98)00138-7","volume":"31","author":"Metz","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib79","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","article-title":"Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial","volume":"94","author":"Antman","year":"1996","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib80","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199509213331203","article-title":"A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty: Helvetica Investigators","volume":"333","author":"Serruys","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib81","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2106\/00004623-199703000-00002","article-title":"Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement","volume":"79","author":"Eriksson","year":"1997","journal-title":"J Bone Joint Surg Am"},{"key":"10.1378\/chest.126.3_suppl.265S_bib82","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJM199711063371901","article-title":"A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement","volume":"337","author":"Eriksson","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib83","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1055\/s-0038-1656063","article-title":"Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial; International Multicentre Hirudin Study Group","volume":"77","author":"Schiele","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib84","first-page":"7095","article-title":"Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin","volume":"29","author":"Maraganore","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.265S_bib85","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/0022-2836(91)90939-4","article-title":"Structure of the hirugen and hirulog 1 complexes of alpha-thrombin","volume":"221","author":"Skrzypczak-Jankun","year":"1991","journal-title":"J Mol Biol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib86","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1042\/bj2870663","article-title":"Hirulog-1 and -B2 thrombin specificity","volume":"287","author":"Witting","year":"1992","journal-title":"Biochem J"},{"key":"10.1378\/chest.126.3_suppl.265S_bib87","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0038-1651573","article-title":"Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans","volume":"69","author":"Fox","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib88","first-page":"33F","article-title":"The use of bivalirudin in patients with renal impairment","volume":"12","author":"Robson","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib89","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or post infarction angina: Hirulog Angioplasty Study Investigators","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib90","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mhj.2001.119374","article-title":"Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: the final report of the Bivalirudin Angioplasty Study","volume":"142","author":"Bittl","year":"2001","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.265S_bib91","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1067\/mhj.2002.122173","article-title":"Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)","volume":"143","author":"Lincoff","year":"2002","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.265S_bib92","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional GPIIb\/IIIa blockade compared with heparin and planned GPIIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.265S_bib93","first-page":"1855","article-title":"Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial","volume":"348","author":"White","year":"2001","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.265S_bib94","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1055\/s-2007-996128","article-title":"Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor","volume":"23","author":"Hursting","year":"1997","journal-title":"Semin Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib95","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4899-2418-6_3","article-title":"Inhibitor binding to thrombin: x-ray crystallographic studies","volume":"340","author":"Banner","year":"1993","journal-title":"Adv Exp Med Biol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib96","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","article-title":"The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction","volume":"20","author":"Swan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.126.3_suppl.265S_bib97","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0735-1097(93)90222-M","article-title":"Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris","volume":"21","author":"Gold","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib98","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/A:1026591023462","article-title":"Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study","volume":"10","author":"Vermeer","year":"2000","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.265S_bib99","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00133080","article-title":"Argatroban during percutaneous transluminal coronary angioplasty: results of a dose-verification study","volume":"3","author":"Herrman","year":"1996","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.265S_bib100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","article-title":"The direct thrombin inhibitor melagatran and its oral prodrug H 376\/95: intestinal absorption properties, biochemical and pharmacodynamic effects","volume":"101","author":"Gustafsson","year":"2001","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.265S_bib101","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0140-6736(02)11469-3","article-title":"Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial","volume":"360","author":"Eriksson","year":"2002","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.265S_bib102","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1055\/s-0037-1613445","article-title":"Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee joint replacement","volume":"89","author":"Eriksson","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib103","first-page":"299","article-title":"The oral direct thrombin inhibitor ximelagatran, and its subcutaneous form melagatran, compared with enoxaparin for prophylaxis of venous thromboembolism in total hip or total knee replacement: the EXPRESS study [abstract]","volume":"100","author":"Eriksson","year":"2002","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.265S_bib104","first-page":"2952","article-title":"Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and enoxaparin to prevent venous thromboembolism after total hip arthroplasty [abstract]","volume":"98","author":"Collwell","year":"2001","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.265S_bib105","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJMoa035162","article-title":"Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement","volume":"349","author":"Francis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1538-7836.2003.00034.x","article-title":"A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I","volume":"1","author":"Eriksson","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.265S_bib107","first-page":"OC003","article-title":"Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study [abstract]","volume":"1","author":"Huisman","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib108","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib109","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0735-1097(03)00255-9","article-title":"Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding tolerability, and safety study","volume":"41","author":"Petersen","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib110","first-page":"2953","article-title":"A long-term follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation [abstract]","volume":"98","author":"Petersen","year":"2001","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.265S_bib111","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-8703(03)00325-9","volume":"146","author":"Halperin","year":"2003","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.265S_bib112","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomized controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.265S_bib113","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.265S_bib114","first-page":"137","article-title":"Heparin-induced transaminase elevations: a prospective study","volume":"31","author":"Guevara","year":"1993","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib115","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1055\/s-0038-1649642","article-title":"Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil","volume":"70","author":"Fujii","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib116","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/01.CIR.92.4.767","article-title":"Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin: a potential link between lipid lowering and fibrinolysis","volume":"92","author":"Brown","year":"1995","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib117","doi-asserted-by":"crossref","first-page":"27942","DOI":"10.1074\/jbc.270.46.27942","article-title":"The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into \u03b2-sheet A","volume":"270","author":"Kvassman","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.265S_bib118","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1172\/JCI117937","article-title":"Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1in vitro","volume":"95","author":"Eitzman","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.265S_bib119","first-page":"916","article-title":"Low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits","volume":"96","author":"Friederich","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib120","doi-asserted-by":"crossref","first-page":"14477","DOI":"10.1074\/jbc.272.22.14477","article-title":"On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B","volume":"272","author":"Sakharov","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.265S_bib121","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1161\/01.CIR.93.7.1328","article-title":"Inducible carboxypeptidase activity: a role in clot lysisin vivo","volume":"93","author":"Redlitz","year":"1996","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.265S_bib122","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood.V94.8.2735.420k30_2735_2743","article-title":"A novel approach to arterial thrombolysis","volume":"94","author":"Klement","year":"1999","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.265S_bib123","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1538-7836.2003.00028.x","article-title":"Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis","volume":"1","author":"Schneider","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib124","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1074\/jbc.M205006200","article-title":"Stabilization versus inhibition of TAFIa by competitive inhibitorsin vitro","volume":"278","author":"Walker","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.265S_bib125","first-page":"177","article-title":"The roles of fibrinogen and fibrin in hemostasis and thrombosis","volume":"29","author":"Mosesson","year":"1992","journal-title":"Semin Hematol"},{"key":"10.1378\/chest.126.3_suppl.265S_bib126","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/10408369609084691","article-title":"Novel aspects of blood coagulation factor XIII: I. Structure, distribution, activation, and function","volume":"33","author":"Muszbek","year":"1996","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1378\/chest.126.3_suppl.265S_bib127","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1055\/s-0038-1656085","article-title":"Tridegin, a novel peptidic inhibitor of factor XIIIa from the leech,Haementeria ghilianii, enhances fibrinolysisin vitro","volume":"77","author":"Seale","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib128","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1042\/bj3240797","article-title":"Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leechHaementeria ghilianii","volume":"324","author":"Finney","year":"1997","journal-title":"Biochem J"},{"key":"10.1378\/chest.126.3_suppl.265S_bib129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00001721-199102000-00025","article-title":"Destabilase, the novel epsilon-(gamma-Glu)-Lys isopeptidase with thrombolytic activity","volume":"2","author":"Baskova","year":"1991","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.126.3_suppl.265S_bib130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s004380050291","article-title":"Genes from the medicinal leech (Hirudo medicinalis) coding for unusual enzymes that specifically cleave endo-epsilon (gamma-Glu)-Lys isopeptide bonds and help to dissolve blood clots","volume":"253","author":"Zavalova","year":"1996","journal-title":"Mol Gen Genet"},{"key":"10.1378\/chest.126.3_suppl.265S_bib131","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1517\/13543784.11.3.397","article-title":"Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent","volume":"11","author":"Walenga","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1378\/chest.126.3_suppl.265S_bib132","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/107602960100700112","article-title":"Synthetic heparin pentasaccharide depolymerization by heparinase: I. Molecular and biological implications","volume":"7","author":"Daud","year":"2001","journal-title":"Clin Appl Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib133","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1055\/s-0038-1649783","article-title":"Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis","volume":"74","author":"Levine","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.265S_bib134","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1056\/NEJM199506223322501","article-title":"A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism","volume":"332","author":"Schulman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib135","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199702063360601","article-title":"The duration of oral anticoagulant therapy after a second episode of venous thromboembolism","volume":"336","author":"Schulman","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib136","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199903253401201","article-title":"A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism","volume":"340","author":"Kearon","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib137","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","article-title":"Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis","volume":"345","author":"Agnelli","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib138","doi-asserted-by":"crossref","first-page":"194S","DOI":"10.1378\/chest.119.1_suppl.194S","article-title":"Antithrombotic therapy in atrial fibrillation","volume":"119","author":"Albers","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.126.3_suppl.265S_bib139","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.265S_bib140","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921531494X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921531494X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:54:20Z","timestamp":1757919260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236921531494X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":140,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S001236921531494X"],"URL":"https:\/\/doi.org\/10.1378\/chest.126.3_suppl.265s","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Anticoagulant Drugs","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.126.3_suppl.265S","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}